A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
NCT ID: NCT05648500
Last Updated: 2026-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
420 participants
INTERVENTIONAL
2022-12-13
2027-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* How well cenerimod works on top of the treatment already being administered.
* How safe cenerimod is for adult patients with Systemic Lupus Erythematosus.
Researchers will compare one dose of cenerimod and a placebo to see how well cenerimod works when it is added to the treatment already being administered.
In this research study approximately 210 participants will receive cenerimod and approximately 210 participants will receive placebo for 12 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT03742037
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
NCT06475742
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
NCT07201129
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cenerimod 4 mg
Participants will receive cenerimod once daily in addition to background SLE therapy.
Cenerimod
Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
Matching placebo
Participants will receive matching placebo once daily in addition to background SLE therapy.
Placebo
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cenerimod
Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
Placebo
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Systemic Lupus Erythematosus (SLE) made at least 6 months prior to Screening, according to 2019 European League Against Rheumatism / American College of Rheumatology Criteria.
* A modified Systemic Lupus Erythematosus Disease Activity Index-2000 (mSLEDAI-2K) score ≥ 6 and clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers). The mSLEDAI-2K score does not include "leukopenia".
* British Isles Lupus Assessment Group-2004 (BILAG) Grade B in ≥ 2 organ systems or a BILAG Grade A in ≥ 1 organ system.
* Physician's Global Assessment (PGA) score ≥ 1.0 on a 0 to 3 visual analog scale.
* Currently treated with one or more of the following SLE background medications:
* Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine).
* Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤1.44 g/day).
* Azathioprine (≤ 2 mg/kg/day).
* Methotrexate (≤ 25 mg/week).
* Oral Corticosteroids (OCS):
* if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
* if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
* Belimumab (≤10 mg/kg every 4 weeks intravenously \[i.v.\], or 200 mg/week subcutaneously \[s.c.\]).
Treatment with antimalarials, mycophenolate mofetil, mycophenolic acid, azathioprine, methotrexate or belimumab must have been started at least 90 days prior to Screening. Treatment with OCS must have been started at least 30 days prior to Screening.
• For women of childbearing potential (WoCBP):
* Negative serum pregnancy test at Screening.
* Agreement to undertake monthly urine pregnancy tests from Randomization up to 6 months after study treatment discontinuation.
* Agreement to use a highly effective method of contraception from Screening (Visit 1) up to 6 months after study treatment discontinuation.
* A clinical mSLEDAI-2K score ≥ 4 with at least 2 points for musculoskeletal or mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers).
* BILAG Grade B in 2 or more organ systems or a BILAG Grade A in 1 or more organ system.
* PGA score ≥ 1.0 on a 0 to 3 visual analog scale.
* Presence of at least one of the following biomarkers of serological evidence of active SLE (in a Screening sample as measured by central laboratory):
* Anti-dsDNA antibodies elevated above normal,
* Antinuclear antibodies with a titer of at least 1:160,
* Anti-Smith antibody elevated above normal.
* Currently treated with one or more of the following SLE background medications that must be stable for at least 30 days prior to Randomization (except OCS, which must be stable for at least 15 days prior to Randomization):
* Antimalarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day chloroquine, ≤ 100 mg/day quinacrine);
* Mycophenolate mofetil (≤ 2 g/day) / mycophenolic acid (≤ 1.44g/day);
* Azathioprine (≤ 2 mg/kg/day);
* Methotrexate (≤ 25 mg/week);
* OCS:
* if OCS is the only SLE background medication: ≥ 7.5 mg/day and ≤ 30 mg/day prednisone or equivalent.
* if OCS is not the only SLE background medication: ≤ 30 mg/day prednisone or equivalent.
* Belimumab (≤ 10 mg/kg every 4 weeks i.v. or ≤ 200 mg/week s.c.).
* WoCBP must have a negative urine pregnancy test at Randomization.
Exclusion Criteria
* Severe active central nervous system lupus or active severe or unstable neuropsychiatric SLE including but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; or mononeuritis multiplex:
* That would make the subject unable to fully understand the ICF; OR
* Where, in the opinion of the investigator/delegate, protocol-specified standard of care is insufficient and the use of a more aggressive therapeutic approach, such as adding i.v. cyclophosphamide and/or high dose i.v. pulse corticosteroid (CS) therapy or other treatments not permitted in the protocol is indicated.
* A diagnosis of mixed connective tissue disease or any history of overlap syndromes of SLE with psoriasis, rheumatoid arthritis, erosive arthritis, scleroderma, autoimmune hepatitis or uncontrolled autoimmune thyroid disease.
* History or presence of Mobitz type II or third-degree atrioventricular block, sick sinus syndrome, symptomatic bradycardia or syncope associated with cardiac disorders.
* Subjects who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, vascular thrombosis, decompensated heart failure requiring hospitalization, or heart failure defined by the New York Heart Association Class III/IV within 6 months prior to Screening.
* Resting heart rate \< 50 bpm as measured by the 12-lead ECG at Screening or at Randomization.
* An elevated QT interval corrected according to Fridericia's formula (QTcF) interval of \> 470 ms (females) / \> 450 ms (males) at Screening or at Randomization.
* History or presence of severe respiratory disease or pulmonary fibrosis, based on medical history, lung function, and chest X-ray (or CT scan as per local guidelines), performed at Screening or within 6 months prior to Screening.
* History of clinically relevant bronchial asthma or chronic obstructive pulmonary disease that has required treatment with oral or parenteral CS for more than a total of 2 weeks within the last 6 months prior to Screening.
* History or presence of malignancy (except for surgically excised and non-recurrent cutaneous basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma), lymphoproliferative disease, or history of total lymphoid irradiation within 10 years prior to Screening.
* Presence of any of the following abnormalities detected during the ophthalmological evaluation and/or by optical coherence tomography (OCT) during screening:
* Macular edema of any cause: diabetic, cystoid, tractional.
* Foveal degeneration, macular hole, macular pseudohole, hereditary or degenerative maculopathies.
* Active uveitis, papilledema.
* Retinal neovascularization of any cause and in any location.
* History of chronic liver or biliary disease (other than Gilbert's Syndrome) or subjects with alanine aminotransferase or aspartate aminotransferase \> 3 × Upper Limit of Normal (ULN) or total bilirubin \> 1.5 × ULN (unless in the context of known Gilbert's Syndrome).
* Significant hematology abnormality at screening assessment:
* lymphocyte count \< 500 /μL (0.5 × 10\^9/L);
* hemoglobin \< 7 g/dL;
* white blood cell count \< 2000/μL (2.0 × 10\^9/L); or
* platelets \< 25000/μL (25 × 10\^9/L).
* Estimated glomerular filtration rate \< 15 mL/min/1.73 m\^2.
* Treatment with the following medications within 15 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:
* β-blockers, diltiazem, verapamil, digoxin, digitoxin, or any other anti-arrhythmic or heart-rate -lowering systemic therapy.
* QT-prolonging drugs with known risk of torsade de pointes irrespective of indication.
* Treatment with the following medications within 30 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:
* Cyclophosphamide, cyclosporine, voclosporin, tacrolimus, sirolimus, etc.
* Pulse methylprednisolone.
* Vaccination with live vaccines (including live vaccines for COVID-19).
* Intra-articular, intramuscular or i.v. CS within 6 weeks prior to Randomization.
* Treatment with the following medications within 90 days or 5 half-lives of the medication (whichever is longer) prior to Randomization:
* Leflunomide.
* i.v. immunoglobulins.
* Treatment with any investigational agent within 90 days or 5 half-lives of the drug (whichever is longer) prior to Randomization.
* Treatment with B cell-depleting biological agents (e.g., rituximab or ocrelizumab) or biological immunosuppressive agents (e.g., anti-tumor necrosis factor \[TNF\], anti-interleukin \[IL\]-1, anti-IL6 therapies), within 12 months prior to Randomization.
* Treatment with anifrolumab within 6 months prior to Randomization.
* Treatment with any of the following medications any time prior to Screening:
* Alemtuzumab,
* Sphingosine-1-phosphate receptor modulators (e.g., fingolimod),
* Subjects previously randomized to cenerimod or placebo in any trial involving cenerimod.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viatris Innovation GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Viatris Innovation GmbH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Medical Foundation
Fullerton, California, United States
California Research Institute
Huntington Park, California, United States
University of Colorado Denver
Aurora, Colorado, United States
RASF-Clinical Research Inc.
Boca Raton, Florida, United States
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States
Omega Research MetroWest, LLC
DeBary, Florida, United States
SouthCoast Research Center, Inc.
Miami, Florida, United States
IRIS Research and Development, LLC
Plantation, Florida, United States
Renew Health Clinical Research LLC
Tampa, Florida, United States
Augusta University
Augusta, Georgia, United States
Advance Quality Medical Research
Orland Park, Illinois, United States
Accurate Clinical Research Inc. - Lake Charles
Lake Charles, Louisiana, United States
Louisiana State University School of Medicine section of Rheumatology
New Orleans, Louisiana, United States
Axon Clinical Research -Baltimore
Baltimore, Maryland, United States
Klein & Associates, M.D., P.A.
Hagerstown, Maryland, United States
June DO, PC
Lansing, Michigan, United States
Bronx Care Health and Wellness Center
The Bronx, New York, United States
DJL Clinical Research, PLLC
Charlotte, North Carolina, United States
Superior Clinical Reseach LLC
Smithfield, North Carolina, United States
University of Oklahoma College of Medicine
Oklahoma City, Oklahoma, United States
Temple University Health Systems/ Lewis Katz School of Medicine
Philadelphia, Pennsylvania, United States
Shelby Research, LLC
Memphis, Tennessee, United States
Allen Arthritis
Allen, Texas, United States
Accurate Clinical Research Inc.
Baytown, Texas, United States
Rheumatology Care Center, PLLC
Bellaire, Texas, United States
Metroplex Clinical Research Center
Dallas, Texas, United States
Houston MD Medspa and Wellness Clinic
Houston, Texas, United States
Accurate Clinical Research Inc.
Houston, Texas, United States
Sun Research Institute
San Antonio, Texas, United States
Fundación Respirar
Buenos Aires, , Argentina
Instituto Medico CER
Buenos Aires, , Argentina
Aprillus Asistencia e Investigacion
Buenos Aires, , Argentina
Hospital Ramos Mejia
Buenos Aires, , Argentina
Arsema Clinica Adventista Belgrano
Buenos Aires, , Argentina
IR Medical Center /Hospital de Día/ Instituto de Reumatología y Traumatología
Mendoza, , Argentina
Instituto CAICI SRL
Rosario, , Argentina
Centro de investigaciones medicas Tucuman
San Miguel de Tucumán, , Argentina
Centro Integral de Reumatología
San Miguel de Tucumán, , Argentina
ICT (Investigaciones Clínicas Tucumán)
San Miguel de Tucumán, , Argentina
Santa Casa de Belo Horizonte
Belo Horizonte, , Brazil
Hospital Brasília
Brasília, , Brazil
Centro Mineiro de Pesquisas
Juiz de Fora, , Brazil
Instituto Méderi de Pesquisa e Saúde
Passo Fundo, , Brazil
Centro Multidisciplinar de Pesquisa Clínica (Irmandade da Santa Casa de Misericórdia de Porto Alegre
Porto Alegre, , Brazil
LMK Servicos Medico S/S
Porto Alegre, , Brazil
IMPAR SERVICOS HOSPITALARES S/A ; Hospital São Lucas
Rio de Janeiro, , Brazil
SER - Serviços Especializados em Reumatologia da Bahia
Salvador, , Brazil
Hospital de Clínicas de Porto Alegre
Santa Cecília, , Brazil
Centro Multidiciplinar de Estudos Clínicos- CEMEC
São Bernardo do Campo, , Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, , Brazil
CPClin - Centro de Pesquisas Clínicas
São Paulo, , Brazil
Ebserh Hospital de Clínicas da Universidade Federal de Uberlândia-HC-UFU
Uberlândia, , Brazil
University Multi-profile Hospital for Active Treatment - Plovdiv AD
Plovdiv, , Bulgaria
"University Multiprofile Hospital for Active Treatment - Pulmed" OOD
Plovdiv, , Bulgaria
Medical Center ArtMed OOD
Plovdiv, , Bulgaria
Outpatient Clinic for Specialized Outpatient Medical Care - Medical Center Kyuchuk Parizh Ltd.
Plovdiv, , Bulgaria
DCC 1 Ruse
Rousse, , Bulgaria
DCC-1-Sevlievo EOOD
Sevlievo, , Bulgaria
DCC "Sveta Anna" EOOD
Sofia, , Bulgaria
Acibadem City Clinic Diagnostic-Consultative Center" EOOD, 127 Okolovrasten pat, Mladost
Sofia, , Bulgaria
DCC Equita EOOD
Varna, , Bulgaria
Clínica de la costa Ltda.
Barranquilla, , Colombia
Bluecare salud SAS
Bogotá, , Colombia
IDEARG (Instituto de Enfermedades Autoinmunes Renato Guzmán)
Bogotá, , Colombia
SERVIMED S.A.S Bucaramanga
Bucaramanga, , Colombia
Fundación Valle de Lili
Cali, , Colombia
Centro de Estudios de Reumatología y Dermatología
Cali, , Colombia
Preventive Care SAS
Chía, , Colombia
Hospital Pablo Tobón Uribe
Medellín, , Colombia
Fundación Centro De Excelencia En Enfermedades Crónicas No Transmisibles-FUNCENTRA
Montería, , Colombia
Healthy Medical Center SAS
Zipaquirá, , Colombia
Hôpital Pitié-Salpêtrière
Paris, , France
CHU Félix Guyon Site Nord
Saint-Denis, , France
CHU de Purpan
Toulouse, , France
Naval Hospital of Athens
Athens, , Greece
General Hospital of Athens "Hippokration"
Athens, , Greece
General Hospital of Athens "Laiko"
Athens, , Greece
University General Hospital "Attikon"
Athens, , Greece
General University Hospital of Larissa
Larissa, , Greece
General University Hospital of Patras
Pátrai, , Greece
Euromedica - Kyanos Stavros
Thessaloniki, , Greece
General Hospital of Thessaloniki "Hippokration"
Thessaloniki, , Greece
424 General Military Hospital
Thessaloniki, , Greece
Sangini Hospital
Ahmedabad, , India
Rajiv Gandhi Government General Hospital
Chennai, , India
Nizam's Institute of medical Sciences
Hyderabad, , India
Maharaja Agrasen Superspeciality Hospital
Jaipur, , India
Radiance Hospital
Nagpur, , India
Shree Hospital and Critical Care Centre.
Nagpur, , India
Assured Care Plus Hospital
Nashik, , India
Coherence Pain & Arthritis Clinics
Pune, , India
Vijaya Ortho & Trauma Centre
Sadashivnagar, , India
Unity Hospital and Trauma Centre
Surat, , India
Hyogo Prefectural Amagasaki General Medical Center
Amagasaki-shi, , Japan
National Hospital Organization Chiba Medical Center Chibahigashi National Hospital
Chiba, , Japan
University of Yamanashi Hospital
Chuo-shi, , Japan
St.Luke's International Hospital
Chūōku, , Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, , Japan
Hiroshima Prefectural Hospital
Hiroshima, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Hitachi, Ltd. Hitachinaka General Hospital
Hitachi-Naka, , Japan
National Kohnodai Medical Center, Japan Institute for Health Security
Ichikawa-shi, , Japan
Tokai University Hospital
Isehara-shi, , Japan
Kakogawa Central City Hospital
Kakogawa-shi, , Japan
Shin-Kokura Hospital
Kitakyushu-shi, , Japan
Kobe University Hospital
Kobe, , Japan
Kobe City Medical Center General Hospital
Kobe, , Japan
Kuwana City Medical Center
Kuwana-shi, , Japan
Toho University - Ohashi Medical Center
Meguro-ku, , Japan
University of Miyazaki Hospital
Miyazaki, , Japan
Nagasaki University Hospital
Nagasaki, , Japan
Chubu Rosai Hospital
Nagoya, , Japan
Chukyo Hospital
Nagoya, , Japan
Nagoya City University Hospital
Nagoya, , Japan
IUHW Narita Hospital
Narita-shi, , Japan
Niigata University Medical and Dental Hospital
Niigata, , Japan
Okayama City General Medical Center Okayama City Hospital
Okayama, , Japan
Ome Medical Center
Ome-shi, , Japan
Osaka Saiseikai Nakatsu Hospital
Osaka, , Japan
Japanese Red Cross Saitama Hospital
Saitama-shi, , Japan
Sainokuni Higashiomiya Medical Center
Saitama-shi, , Japan
Toho University Sakura Medical Center
Sakura-shi, , Japan
Hokkaido University Hospital
Sapporo, , Japan
National Hospital Organization Hokkaido Medical Center
Sapporo, , Japan
Tohoku Medical and Pharmaceutical University Hospital
Sendai, , Japan
Showa Medical University East Hospital
Shinagawa-ku, , Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, , Japan
Tomakomai City Hospital
Tomakomai-shi, , Japan
Yokohama City Minato Red Cross Hospital
Yokohama, , Japan
Panamerican Clinical Research Mexico S.A. de C.V.
Cuernavaca, , Mexico
Consultorio Privado de Especialidad
Guadalajara, , Mexico
Centro de Estudios de Investigación Básica y Clínica, S.C.
Guadalajara, , Mexico
Consultorio Médico de Reumatología - Hospital Aranda de la Parra
León, , Mexico
Biológicos Especializados S.A. de C.V.
Mexico City, , Mexico
CITER, Centro de Investigación y Tratamiento de las Enfermedades Reumáticas S.A. de C.V.
Mexico City, , Mexico
Unidad de Atención Médica e Investigación en Salud
Mérida, , Mexico
Centro de Investigación Clínica Chapultepec S. A. de C. V.
Morelia, , Mexico
SMIQ, S. de R.L. de C.V.
Querétaro, , Mexico
Centro de Atención e Investigación Cardiovascular del Potosí, S.C.
San Luis Potosí City, , Mexico
Unidad de Investigaciones Reumatológicas A.C
San Luis Potosí City, , Mexico
Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V.
Zapopan, , Mexico
Chong-Hua Hospital
Cebu City, , Philippines
Davao Doctors Hospital
Davao City, , Philippines
Mary Mediatrix Medical Center
Lipa, , Philippines
Makati Medical Center
Makati, , Philippines
UP-PGH
Manila, , Philippines
Far Eastern University - Nicanor Reyes Medical Foundation
Quezon City, , Philippines
Jose R. Reyes Memorial Medical Center
Santa Cruz, , Philippines
INTER CLINIC Piotr Adrian Klimiuk
Bialystok, , Poland
Centrum Medyczne Pratia Częstochowa
Częstochowa, , Poland
Centrum Medyczne Angelius Provita
Katowice, , Poland
Vita Longa Sp. z o.o.
Katowice, , Poland
Małopolskie Badania Kliniczne
Krakow, , Poland
Centrum Medyczne Plejady
Krakow, , Poland
Velocity Nova Sp. z o. o.
Lublin, , Poland
Zespół Poradni Specjalistycznych REUMED
Lublin, , Poland
Malwa-Med Iwona Chlebicka
Wroclaw, , Poland
Neomed Brasov
Brasov, , Romania
SC Sana Monitoring SRL
Bucharest, , Romania
Delta Health Care SRL
Bucharest, , Romania
Spitalul Clinic Dr. Ion Cantacuzino
Bucharest, , Romania
Spitalul Clinic Judetean de Urgentã Craiova
Craiova, , Romania
SC Medaudio-Optica SRL
Râmnicu Vâlcea, , Romania
Pusan National University Hospital
Busan, , South Korea
Catholic University of Daegu (Daegu Catholic University Medical Center)
Daegu, , South Korea
Seoul National University Hospital
Junggu, , South Korea
Hanyang University Hospital, Seongdong-gu
Seoul, , South Korea
Ewha University Mokdong Hospital, Yangcheon-gu
Seoul, , South Korea
KonKuk University Medical Center, Gwangjin-gu
Seoul, , South Korea
Seoul Saint Mary's Hospital of the Catholic University of Korea, Seocho-gu
Seoul, , South Korea
Kaohsiung Medical University Hospital
Kaohsiung City, , Taiwan
Far Eastern Memorial Hospital
New Taipei City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Chi Mei Medical Center
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Medical University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Cheng Hsin General Hospital
Taipei, , Taiwan
TRI-Service General Hospital
Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan, , Taiwan
Vajira Hospital
Bangkok, , Thailand
King Chulalongkorn Memorial Hospital
Bangkok, , Thailand
Phramongkutklao Hospital (PMK)
Bangkok, , Thailand
Rajavithi Hospital
Bangkok, , Thailand
Ramathibodi Hospital
Bangkok, , Thailand
Maharaj Nakorn Chiang Mai Hospital, Division of Rheumatology
Chiang Mai, , Thailand
Srinagarind Hospital, Khon Kaen University
Khon Kaen, , Thailand
Songklanagarind Hospital
Songkhla, , Thailand
Fort Sunpasithiprasong Hospital
Ubon Ratchathani, , Thailand
Communal Non-Commercial Enterprise "Cherkasy Regional Hospital of Cherkasy Regional Council"
Cherkasy, , Ukraine
Communal Non-Commercial Enterprise "Khmelnytsky Regional Hospital" of Khmelnytsky Regional Council
Khmelnytskyi, , Ukraine
Clinic of Modern Rheumatology
Kyiv, , Ukraine
Kyiv City Clinical Hospital #3
Kyiv, , Ukraine
Kyiv Railway Clinical Hospital #2 of Branch "Health Center" of Joint-Stock Company "Ukrainian Railway"
Kyiv, , Ukraine
State Ins Nat Scie Cen M.D.Strazhesko Ins of Cardio Clin
Kyiv, , Ukraine
Communal Non-Commercial Enterprise of Kyiv Regional Council Kyiv Clinical Regional Hospital, Consultation and Diagnostic Center
Kyiv, , Ukraine
Volyn Regional Clinical Hospital
Lutsk, , Ukraine
Com Non-Com Entr of Lviv Reg Coun "Lviv Reg Clin Hos, Rheu Dprt, Danylo Halytsky Lviv Nat Med Uni
Lviv, , Ukraine
Medical Center of Limited Liability Company "Kalyna. Center of Modern Medicine
Lviv, , Ukraine
Medical Centre "Academical Medical Group" LLC
Lviv, , Ukraine
Uzhhorod City Multidisciplinary Clinical Hospital
Uzhhorod, , Ukraine
Private Small-Scale Enterprise Medical Centre "Pulse", Therapeutical Department
Vinnytsia, , Ukraine
Municipal Nonprofit Institution "Vinnytsia City Clinical Hospital #1"
Vinnytsia, , Ukraine
Communal Enterprise "Hospital #1" of Zhytomyr City Council, Consultation and Treatment Department "Scientific Research Center"
Zhytomyr, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2025 Jan;7(1):e21-e32. doi: 10.1016/S2665-9913(24)00246-7. Epub 2024 Nov 22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-002814-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2024-515870-28-00
Identifier Type: CTIS
Identifier Source: secondary_id
ID-064A301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.